Prophylactic Favipiravir for Healthcare Workers in COVID-19 Pandemic

Favipiravir prophylactic to reduce the involvement of health care workers in the COVID-19 epidemic

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20150107020592N30

Enrollment

Registered

2020-07-10

Start date

2020-03-20

Completion date

Unknown

Last updated

2020-07-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

covid-19. covid19 disease

Interventions

Intervention group: Thirty people in the intensive care unit who are in direct contact with COVID-positive patients have been studied and given Favipiravir 200 twice a day for three days a week for tw

Eligibility

Sex/Gender

All

Age

20 Years to No maximum

Inclusion criteria

Inclusion criteria: Age over 20 years Nurses in the intensive care unit Satisfaction with entering the plan

Exclusion criteria

Exclusion criteria: Sensitivity to antiviral drugs

Design outcomes

Primary

Measure	Time frame
Infection with Covid 19. Timepoint: Three weeks after starting treatment. Method of measurement: Nasal swap prc covid-19.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactSeyed Mohammad Reza Hashemian

Shahid Beheshti University of Medical Sciences

smrhashemian@sbmu.ac.ir+98 912 111 9279

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026